arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Apogee Therapeutics, Inc.

APGE

$134.83 ▲ +0.32 (+0.24%) at close

16 Visible periods

14 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Apogee Therapeutics, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $9.4B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC —

FCF / Share $-0.80

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-74.11M

↓ -33.9% —

FCF / Share Free cash flow per share

$-0.80

↑ +12.1% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

FCF / Net IncomeFCF / Net Income of 0.91x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
EPS Growth YoY (%)	-11.6% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	13.4% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-29.1% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-88.3% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-48.4% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-271.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-68.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	84.1% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	74.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	N/M	94.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-160.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-33.9% Weak ↑ Weak Improving Year-over-year change in net income	-3.2% Weak ↑ Weak Improving Year-over-year change in net income	-72.4% Weak ↑ Weak Improving Year-over-year change in net income	-72.4% Weak ↑ Weak Improving Year-over-year change in net income	-72.4% Weak ↑ Weak Improving Year-over-year change in net income	-111.8% Weak ↑ Weak Improving Year-over-year change in net income	-156.2% Weak ↓ Weak Declining Year-over-year change in net income	-156.2% Weak → Weak Stable Year-over-year change in net income	-156.2% Weak ↑ Weak Improving Year-over-year change in net income	-126.6% Weak ↑ Weak Improving Year-over-year change in net income	-190.9% Weak Weak Year-over-year change in net income	-190.9% Weak Weak Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	12.1% Fair ↑ Fair Improving Year-over-year change in free cash flow	—	-21.2% Weak ↑ Weak Improving Year-over-year change in free cash flow	-106.9% Weak Weak Year-over-year change in free cash flow	-42.3% Weak Weak Year-over-year change in free cash flow	—	—	—	69.8% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Effective Tax Rate (%) (%)	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.13x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.35x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	0.84x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Return on Capital (%) (%)	-6.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-11.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-10.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-4.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	—	-5.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-14.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-9.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Net Debt (USD)	$-451.80M	$-131.55M	$-107.91M	$-124.19M	$-106.92M	$-141.79M	$-118.78M	$-307.30M	$-485.46M	$-118.32M	—	—	$-141.33M	$-151.89M	—	—

📊 What does each share earn? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Basic EPS, GAAP (USD)	$-1.06	$-1.03	$-1.11	$-1.13	$-0.95	$-1.19	$-0.86	$-0.60	$-0.64	$-0.32	$-0.51	$-3.78	$-2.51	$0.84	$-9.46	$-1.45
Free Cash Flow per Share (USD)	$-0.80	—	$-0.92	$-1.07	$-0.91	—	$-0.76	$-0.52	$-0.64	—	—	—	$-2.11	—	—	—
Basic Weighted Avg Shares (shares)	69.67M	—	58.77M	58.43M	58.20M	—	56.80M	56.52M	50.19M	—	41.23M	5.00M	5.00M	—	2.08M	1.25M

🏦 How resilient is the balance sheet? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Working Capital (USD)	$1.04B	$713.45M	$506.05M	$484.57M	$488.57M	$501.15M	—	—	$799.06M	—	$409.24M	$113.05M	—	$142.07M	—	—

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗
Depreciation Expense (USD)	$408.00K	$406.00K	$400.00K	$400.00K	$207.00K	$76.00K	$48.00K	$36.00K	$29.00K	—	—	—	—	—	—	—
Net Income, GAAP (USD)	$-74.11M	$-69.39M	$-55.34M	$-55.34M	$-55.34M	$-67.22M	$-32.09M	$-32.09M	$-32.09M	$-31.73M	$-12.53M	$-12.53M	$-12.53M	$-14.01M	$-4.30M	$-4.30M
Operating Cash Flow (USD)	$-55.57M	$-62.69M	$-54.26M	$-62.03M	$-48.48M	$-67.71M	$-42.52M	$-29.30M	$-31.64M	$-29.75M	—	—	$-10.56M	$-9.19M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 16 quarters

Apogee Therapeutics, Inc.

Analytical Summary

16-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare APGE with peers